Metabolic syndrome is a cluster of metabolic abnormalities that often co–exist and would lead to a marked increase in the risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) including obesity, hyperglycemia, dyslipidemia and hypertension [1–7]. The essence of the metabolic syndrome  lies in the clustering of these risk factors, whose presence has extensively been reported to point to an almost five–fold elevation in CVD risk [6,8–11]. Metabolic syndrome is common in individuals with diabetes mellitus (DM) and significantly more common in patients with T2DM than in those with type 1 diabetes mellitus (T1DM) [12–14] .The total CVD risk attributable to the syndrome has been observed to exceed the sum of the risk from each of the separate components [8,15]. Hence, it becomes a great burden on public health and clinical practice [16]. Metabolic syndrome consists of a multi–factorial set of indicators [17–19]. The World Health Organization (WHO) definition [5] was the first to tie together the key components of Metabolic syndrome : insulin resistance, obesity, dyslipidemia and hypertension, where the presence of insulin resistance is mandatory. With that said, this definition also allows patients with T2DM to be diagnosed with Metabolic syndrome  if they meet the other criteria.  Although different terms have been used for the insulin resistance syndrome or syndrome X, the term Metabolic syndrome was coined by Adult Treatment Panel III– National Cholesterol Education Program (ATP III– NCEP) to use a common definition in global context(20).